****

**TABLE OF CONTENTS**

[1. REPORT OVERVIEW 19](#_Toc116211917)

[1.1 Statement of the Report 19](#_Toc116211918)

[1.2 Executive Summary 21](#_Toc116211919)

[1.3 Introduction 22](#_Toc116211920)

[2. CAR-T CELL THERAPY: TECHNOLOGY DEVELOPMENT 24](#_Toc116211921)

[2.1 CAR-T Cell 25](#_Toc116211922)

[2.2 Evolution of CAR-T Cell Development 26](#_Toc116211923)

[2.2.1 The CAR-T Cell Family 26](#_Toc116211924)

[2.2.1.1 First Generation CARs 27](#_Toc116211925)

[2.2.1.2 Second Generation CARs 28](#_Toc116211926)

[2.2.1.3 Third Generation CARs 28](#_Toc116211927)

[2.2.1.4 Fourth Generation CARs 29](#_Toc116211928)

[2.2.1.5 Fifth Generation CARs 29](#_Toc116211929)

[2.3 Antigens Present on Hematological Malignant Cells 30](#_Toc116211930)

[2.4 Tools for Inserting Receptor Genes into T Cells 31](#_Toc116211931)

[2.5 Transforming T Cells into CAR-T Cells 32](#_Toc116211932)

[2.6 The Seven CAR-T Therapies Available in the Market: A Brief Overview 33](#_Toc116211933)

[2.7 Toxicities Associated with CAR-T Treatment 36](#_Toc116211934)

[2.8 Strategies for the Future of CAR-T Therapies 37](#_Toc116211935)

[2.8.1 Switchable CARs (sCARs) 38](#_Toc116211936)

[2.8.2 Suicide Genes to Destroy CAR-T Cells In Vivo 39](#_Toc116211937)

[2.8.3 Transient Transfection 39](#_Toc116211938)

[2.8.4 Affinity Tuned CARs 39](#_Toc116211939)

[2.8.5 Armored CARs 39](#_Toc116211940)

[2.8.6 Shift from Liquid Cancers to Solid Tumors 40](#_Toc116211941)

[2.8.7 Focus on Shortening Hospital Stay 40](#_Toc116211942)

[2.8.8 Focus on Discovering New Antigens 41](#_Toc116211943)

[2.8.9 Shifting from Autologous to Allogeneic CAR-T Therapies 41](#_Toc116211944)

[2.8.10 CAR-T for the Masses 42](#_Toc116211945)

[2.8.11 New In Vivo CAR-T Approach 42](#_Toc116211946)

[2.8.12 Combination with mRNA Vaccine 43](#_Toc116211947)

[2.8.13 Combination with Oncolytic Virus 43](#_Toc116211948)

[2.9 Direct Competion between Autologous CAR-T Therapies 43](#_Toc116211949)

[3. CAR-T CELL THERAPY: PRODUCT DEVELOPMENT 44](#_Toc116211950)

[3.1 History of Development of CAR-T Cells 45](#_Toc116211951)

[3.2 Top Ten Milestones Crossed by CAR-T Therapy 46](#_Toc116211952)

[3.2.1 First Pediatric Patient to Receive CAR-T Therapy 46](#_Toc116211953)

[3.2.2 CAR-T Granted Breakthrough Therapy Designation 46](#_Toc116211954)

[3.2.3 The Beginning of CAR-T Development to Combat Solid Cancers 46](#_Toc116211955)

[3.2.4 First CRISPR CAR-T Built 47](#_Toc116211956)

[3.2.5 The First Two CAR-T Approvals 47](#_Toc116211957)

[3.2.6 EMA’s Approval for Kymriah and Yescarta 47](#_Toc116211958)

[3.2.7 Approval of Tecartus, Breyanzi and Abecma 47](#_Toc116211959)

[3.2.8 NMPA Approval of Relma-cel (Carteyva) 48](#_Toc116211960)

[3.2.9 Approval of Carvykti 48](#_Toc116211961)

[3.3 Current Status of CAR-T Therapy Products 48](#_Toc116211962)

[3.3.1 Kymriah (Tisagenlecleucel) 49](#_Toc116211963)

[3.3.1.1 Kymriah’s Mechanism of Action 50](#_Toc116211964)

[3.3.1.2 Clinical Trials on Kymriah 51](#_Toc116211965)

[3.3.2 Yescarta (Axicabtagene ciloleucel) 51](#_Toc116211966)

[3.3.2.1 Mechanism of Action 52](#_Toc116211967)

[3.3.2.2 Yeskarta on Clinical Trials 53](#_Toc116211968)

[3.3.3 Tecartus (Brexucabtagene autoleucel) 53](#_Toc116211969)

[3.3.3.1 Tecartus Approvals 53](#_Toc116211970)

[3.3.3.2 Mechanism of Action 54](#_Toc116211971)

[3.3.3.3 Clinical Trials on Tecartus 54](#_Toc116211972)

[3.3.4 Breyanzi (Lisocabtagene maraleucel) 55](#_Toc116211973)

[3.3.5 Abecma (Idecabtagene vicleucel) 56](#_Toc116211974)

[3.3.5.1 Regulatory Approvals for Abecma 56](#_Toc116211975)

[3.3.5.2 Mechanism of Action 57](#_Toc116211976)

[3.3.5.3 Clinical Trials on Abecma 57](#_Toc116211977)

[3.3.6 Relma-Cel (Relmacabtagene autoleucel) 58](#_Toc116211978)

[3.3.7 Carvykti (Ciltacabtagene autoleucel) 59](#_Toc116211979)

[3.3.7.1 Regulatory Approvals for Carvykti 60](#_Toc116211980)

[3.3.7.2 Mechanism of Action 60](#_Toc116211981)

[3.3.7.3 Clinical Trials on Carvykti 60](#_Toc116211982)

[3.4 Other Promising CAR-T Product Candidates 61](#_Toc116211983)

[3.4.1 ALLO-501 62](#_Toc116211984)

 [3.4.2 CTX-110 62](#_Toc116211985)

[3.4.3 UCART19 62](#_Toc116211986)

[3.4.4 AUT01 62](#_Toc116211987)

[3.4.5 JCARH125 63](#_Toc116211988)

[3.4.6 PBCAR20A 63](#_Toc116211989)

[3.4.7 UCART123 63](#_Toc116211990)

[3.4.8 PRGN-3006 63](#_Toc116211991)

[3.4.9 UCART22 64](#_Toc116211992)

[3.4.10 UCARTCS1 64](#_Toc116211993)

[3.5 Transformative Potential of CAR-T Therapy 64](#_Toc116211994)

[3.6 Cancer Population Addressed by CAR-T Therapy 65](#_Toc116211995)

[3.7 Advantages of CAR-T Cell Therapy 65](#_Toc116211996)

[3.8 Disadvantages of CAR-T Therapy 66](#_Toc116211997)

[4. SCALABLE MANUFACTURING OF CAR-T CELLS 67](#_Toc116211998)

[4.1 The Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies 67](#_Toc116211999)

[4.2 The Evolution of CAR-T Cell Manufacturing Platforms 69](#_Toc116212000)

[4.2.1 Open vs. Closed Systems 69](#_Toc116212001)

[4.2.2 Manual Processing vs. Automation 70](#_Toc116212002)

[4.2.3 Autologous vs. Allogeneic Manufacturing 71](#_Toc116212003)

[4.4 Operating Expenses in Autologous CAR-T Manufacturing 71](#_Toc116212004)

[4.5 Operating Expenses in Allogeneic CAR-T Manufacturing 72](#_Toc116212005)

[5. CAR-T TARGET ANTIGENS 74](#_Toc116212006)

[5.1 CAR-T Target Antigens on Hematalogical Malignancies 74](#_Toc116212007)

[5.2 CAR-T Target Antigens on Solid Tumors 75](#_Toc116212008)

[5.3 Common Antigens Targeted by CAR-T Cells in Clinical Trials 76](#_Toc116212009)

[5.3.1 Cluster of Differentiation 19 (CD19) 77](#_Toc116212010)

[5.3.2 Mesothelin 77](#_Toc116212011)

[5.3.3 B-Cell Maturation Agent (BCMA) 77](#_Toc116212012)

[5.3.4 GD2 78](#_Toc116212013)

[5.3.5 Glypican-3 (GPC3) 78](#_Toc116212014)

[5.3.6 Cluster Differentiation-22 (CD22) 78](#_Toc116212015)

[6. CAR-T PATENT LANDSCAPE 79](#_Toc116212016)

[6.1 Geographical Origin of CAR-T Patent Applications 81](#_Toc116212017)

[6.2 Top Ten CAR-T Patent Jurisdictions 81](#_Toc116212018)

[6.3 Affiliations of CAR-T Patent Applicants 82](#_Toc116212019)

[6.4 Top 20 Companies in CAR-T Patent Landscape 83](#_Toc116212020)

[6.5 Top 20 Research Centers in CAR-T Patent Landscape 84](#_Toc116212021)

[6.6 Top Ten CAR-T Inventors 85](#_Toc116212022)

[6.7 Top Five CAR-T Patents with Most Family Members 86](#_Toc116212023)

[6.8 Top Five CAR-T Patents with Most Inventors in Co-Authorship 87](#_Toc116212024)

[6.9 Top Five Patents with Most Co-Applicants 88](#_Toc116212025)

[6.10 Top 5 CAR-T Patents with Most Co-Applicants 88](#_Toc116212026)

[7. CAR-T CLINICAL TRIAL LANDSCAPE 89](#_Toc116212027)

[7.1 Most Addressed Indications in Clinical Trials 89](#_Toc116212028)

[7.2 Current Focus of Ongoing Clinical Trials 89](#_Toc116212029)

[7.3 Countries with Most Clinical Trials 89](#_Toc116212030)

[7.4 Phase of Clinical Trial Studies 91](#_Toc116212031)

[7.5 CAR-T Clinical Trials for Hematalogical Malignancies 91](#_Toc116212032)

[7.6 Simultaneous Targets by One CAR-T 92](#_Toc116212033)

[7.7 CAR-T Generations Used in Clinical Trials 93](#_Toc116212034)

[7.8 CAR-T Clinical Trials Focusing on Solid Tumors 93](#_Toc116212035)

[7.9 CAR-T Targeted Biomarkers in Clinical Trials 94](#_Toc116212036)

[7.10 CAR-T Targeted Biomarkers in the U.S. Clinical Trials 95](#_Toc116212037)

[7.11 CAR-T Targeted Biomarkers in Chinese Clinical Trials 96](#_Toc116212038)

[7.12 CAR-T Targeted Indications in the U.S. Clinical Trials 97](#_Toc116212039)

[7.13 Indications Addressed by CAR-T Clinical Trials in China 98](#_Toc116212040)

[7.14 Hematological Malignancies v.s. Solid Cancers in CAR-T Clinical Trials 99](#_Toc116212041)

[7.15 CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S. 100](#_Toc116212042)

[7.16 CAR-T Clinical Trial Sponsor Companies & Institutions in China 102](#_Toc116212043)

[7.17 CAR-T Clinical Trial Sponsor Companies & Institutions in other Countries 105](#_Toc116212044)

[7.18 Improved CAR-T Constructs in Clinical Trials 107](#_Toc116212045)

[7.18.1 CAR-T with PD1Fc 107](#_Toc116212046)

[7.18.2 CAR-T with Truncated with EGFR (EGFRt) 107](#_Toc116212047)

[7.18.3 CAR-T with IL7 and CCL19 107](#_Toc116212048)

[7.18.4 CAR-T with PD1/CD28 Switch Receptor 108](#_Toc116212049)

[7.18.5 CAR-T with PD1 shRNA Expressing Cassette 108](#_Toc116212050)

[7.18.6 CAR-T with CTLA-4/PD-1 Antibody 108](#_Toc116212051)

[7.18.7 CAR-T with PD-1 Antibodies 108](#_Toc116212052)

[7.19 Distribution of CAR-T Trials by Type of SeFv Used 114](#_Toc116212053)

[7.20 Distribution of CAR-T Clinical Trials by Type of Vectors Used 114](#_Toc116212054)

[8. PUBLISHED CAR-T SCIENTIFIC PAPERS IN PUBMED.GOV & NIH FUNDING 116](#_Toc116212055)

[8.1 PubMed.gov Published Papers on the Five Generation of CARs 116](#_Toc116212056)

[8.2 PubMed.gov Papers Published on Autologous and Allogeneic CAR-Ts 117](#_Toc116212057)

[8.3 Published CAR-T PubMed Papers on Solid & Liquid Cancers 118](#_Toc116212058)

[8.4 NIH Funding for CAR-T Research in 2022 120](#_Toc116212059)

[9. DEALS IN CAR-T THERAPY SPACE 122](#_Toc116212060)

[9.1 Most Recent CAR-T Deals 122](#_Toc116212061)

[9.1.1 Autolus Therapeutics/Bristol Myers Squibb 122](#_Toc116212062)

[9.1.2 ArsenalBio/Genentech 122](#_Toc116212063)

[9.1.3 Chugai Pharmaceutical/Noile Immune Biotech 122](#_Toc116212064)

[9.1.4 Roche/Poseida Therapeutics 123](#_Toc116212065)

[9.1.5 Oxford Biomedica/Undisclosed U.S. Company 123](#_Toc116212066)

[9.1.6 Immatics/Bristol Myers Squibb 123](#_Toc116212067)

[9.1.7 Galapagos/CellPoint/AboundBio 124](#_Toc116212068)

[9.1.8 Coeptis/University of Pittsburgh 124](#_Toc116212069)

[9.1.9 Pregene/CellPont 124](#_Toc116212070)

[9.1.10 Intellia/Kyverna 125](#_Toc116212071)

[9.2 Funding for CAR-T Therapy in H1 2022 125](#_Toc116212072)

[9.2.1 Neukio Bio 125](#_Toc116212073)

[9.2.2 Arsenal Biosciences 125](#_Toc116212074)

[9.2.3 Eyestem 126](#_Toc116212075)

[9.2.4 Legend Biotech 126](#_Toc116212076)

[9.2.5 Immuneel Therapeutics 126](#_Toc116212077)

[9.2.6 Tessa Therapeutics 127](#_Toc116212078)

[9.2.7 Elicera Therapeutics 127](#_Toc116212079)

[9.2.8 Inceptor Bio 127](#_Toc116212080)

[9.2.9 AvenCell Therapeutics 127](#_Toc116212081)

[9.2.10 Ucello Theraputics 128](#_Toc116212082)

[9.2.11 Kyverna Therapeutics 128](#_Toc116212083)

[10. REIMBURSEMENT FOR CAR-T THERAPIES 129](#_Toc116212084)

[10.1 Potential Barriers to CAR-T Treatments 129](#_Toc116212085)

[10.1.1 Patient Barriers 129](#_Toc116212086)

[10.1.2 Limited Number of Treatment Centers 129](#_Toc116212087)

[10.1.3 Travel, Lodging & Meal Expenses 130](#_Toc116212088)

[10.1.4 Utilization Management Policies 130](#_Toc116212089)

[10.1.5 Out-of-Pocket Costs 130](#_Toc116212090)

[10.1.6 Geography 131](#_Toc116212091)

[10.1.7 Logistics of Follow-Up 131](#_Toc116212092)

[10.1.8 Reimbursement Uncertainty 131](#_Toc116212093)

[10.2 Manufacturer Challenges 132](#_Toc116212094)

[10.2.1 Lingering Manufacturing Issues 132](#_Toc116212095)

[10.2.2 Difficulties with Scaling Up 132](#_Toc116212096)

[10.3 CAR-T Reimbursement Updated for FY 2023 IPPS Final Rule 133](#_Toc116212097)

[10.3.1 Payment Changes for CAR-T Cases 133](#_Toc116212098)

[10.3.2 High-Cost Outlier Payments 133](#_Toc116212099)

[10.4 Use of 2021 Data to Establish Payment 133](#_Toc116212100)

[10.4.1 Adjustment for Clinical Trial Cases 134](#_Toc116212101)

[10.4.2 Product NTAP Decisions 134](#_Toc116212102)

[10.5 Reimbursement for CAR-T Therapy in Europe 135](#_Toc116212103)

[10.5.1 Cost Components of Pre- and Post-CAR-T Cell Therapy 136](#_Toc116212104)

[10.5.2 Average Total Costs Pre- and Post CAR-T Cell Administration in E.U. 137](#_Toc116212105)

[10.6 Outcomes-Based Reimbursement for CAR-T Therapies in Europe 137](#_Toc116212106)

[10.6.1 France 137](#_Toc116212107)

[10.6.2 Germany 138](#_Toc116212108)

[10.6.3 Italy 139](#_Toc116212109)

[10.6.4 Spain 139](#_Toc116212110)

[10.6.5 Reimbursement for CAR-T Therapies in U.K. 140](#_Toc116212111)

[10.7 CAR-T Cell Treated Patients Registered in EBMT Registry 140](#_Toc116212112)

[11. BLOOD CANCERS: INCDENCE AND AVAILABLE TREATMENTS 142](#_Toc116212113)

[11.1 Lymphoma 143](#_Toc116212114)

[11.1.1 Hodgkin Lymphoma (HL) 143](#_Toc116212115)

[11.1.2 Non-Hodgkin Lymphoma (NHL) 143](#_Toc116212116)

[11.1.3 Difuse Large B Cell Lymphoma (DLBCL) 144](#_Toc116212117)

[11.1.4 Follicular Lymphoma (FL) 144](#_Toc116212118)

[11.2 Leukemia 144](#_Toc116212119)

[11.2.1 Types of Leukemia 145](#_Toc116212120)

[11.2.1.1 Acute Myeloid Leukemia (AML) 145](#_Toc116212121)

[11.2.1.2 Acute Lymphoblastic Leukemia (ALL) 146](#_Toc116212122)

[11.2.1.3 Chronic Myeloid Leukemia (CML) 146](#_Toc116212123)

[11.2.1.4 Chronic Lymphocytic Leukemia (CLL) 146](#_Toc116212124)

[11.2.1.5 Multiple Myeloma (MM) 147](#_Toc116212125)

[11.3 Treatment Options for Blood Cancers 147](#_Toc116212126)

[11.3.1 Chemotherapy 148](#_Toc116212127)

[11.3.2 Radiation Therapy 149](#_Toc116212128)

[11.3.3 Targeted Therapy 149](#_Toc116212129)

[11.3.4 Stem Cell Transplantation 150](#_Toc116212130)

[11.3.5 Immunotherapy 151](#_Toc116212131)

[11.3.5.1 Monoclonal Antibodies (mAbs) 151](#_Toc116212132)

[11.3.6 Adoptive Cell Transfer Therapy/T Cell Transfer Therapy 152](#_Toc116212133)

[11.4 The Staggering Cost of Cancer Therapies 152](#_Toc116212134)

[12. MARKET ANALYSIS 154](#_Toc116212135)

[12.1 Global Market for CAR-T Cell Therapy by Product 154](#_Toc116212136)

[12.2 Global Market for CAR-T Therapy by Geography 158](#_Toc116212137)

[12.3 Global Market for CAR-T Therapy by Indication 159](#_Toc116212138)

[13. BARRIERS & STRATEGIES FOR SUCCESS IN CAR-T 2.0 MARKET PLACE 161](#_Toc116212139)

[13.1 Barriers to CAR-T 2.0 Commercial Success 161](#_Toc116212140)

[13.2 Capacity Constraints 161](#_Toc116212141)

[13.3 Competition among Manufacturers 161](#_Toc116212142)

[13.4 Competition from other Treatments 162](#_Toc116212143)

[13.5 Market Development Strategies for CAR-T 2.0 162](#_Toc116212144)

[13.5.1 Effective Physician Education 162](#_Toc116212145)

[13.5.2 Logistical Excellence 162](#_Toc116212146)

[13.5.3 Evidence Generation 162](#_Toc116212147)

[14. CAR-T COMPANIES: AN OVERVIEW 163](#_Toc116212148)

[14.1 Abintus Bio, Inc. 163](#_Toc116212149)

[14.2 Adicet Bio 164](#_Toc116212150)

[14.2.1 Gamma Delta T Cells 164](#_Toc116212151)

[14.2.2 Proprietary Cell Platform Process 164](#_Toc116212152)

[14.2.3 Pipeline 165](#_Toc116212153)

[14.3 AffyImmune Therapeutics, Inc. 166](#_Toc116212154)

[14.3.1 Affinity-Tuned CARs 166](#_Toc116212155)

[14.3.2 Real-Time CAR-T Cell Monitoring 166](#_Toc116212156)

[14.4 Alaunos Therapeutics, Inc. 167](#_Toc116212157)

[14.5 Aleta BioTherapeutics 168](#_Toc116212158)

[14.5.1 Aleta’s CAR-T Engager Pipeline 168](#_Toc116212159)

[14.6 Allogene Therapeutics 169](#_Toc116212160)

[14.6.1 AlloCAR-T 169](#_Toc116212161)

[14.7 Anixa Biosciences, Inc. 170](#_Toc116212162)

[14.8 Appia Bio 171](#_Toc116212163)

[14.9 Arbele Ltd. 172](#_Toc116212164)

[14.9.1 AI-CAR-T/NK Cell Platform 172](#_Toc116212165)

[14.10 Arcellx 173](#_Toc116212166)

[14.10.1 D-Domain Technology 173](#_Toc116212167)

[14.10.2 ddCAR 173](#_Toc116212168)

[14.10.3 ARC-SparX 174](#_Toc116212169)

[14.11 Artiva Biotherapeutics 175](#_Toc116212170)

[14.11.1 Artiva’s AlloNK Platform 175](#_Toc116212171)

[14.11.2 Artiva’s CAR-NK Platform 175](#_Toc116212172)

[14.12 Atara Biotherapeutics 176](#_Toc116212173)

[14.12.1 Technology 176](#_Toc116212174)

[14.12.2 Atara’s Robust Pipeline 177](#_Toc116212175)

[14.13 Aurora BioPharma 177](#_Toc116212176)

[14.14 Autolus Therapeutics plc 178](#_Toc116212177)

[14.14.1 Technology 178](#_Toc116212178)

[14.14.2 CAR-T Cell Production 178](#_Toc116212179)

[14.14.3 Manufacturing 178](#_Toc116212180)

[14.14.4 Autolus’ Therapies in Development 179](#_Toc116212181)

[14.14.5 obe-cel 179](#_Toc116212182)

[14.15 AvenCell Europe GmbH 180](#_Toc116212183)

[14.15.1 AvenCell’s Proprietary Platforms 180](#_Toc116212184)

[14.15.2 UniCAR 180](#_Toc116212185)

[14.15.3 RevCAR 180](#_Toc116212186)

[14.15.4 TCE 181](#_Toc116212187)

[14.15.5 AvenCell’s Clinical and Preclinical Pipeline 181](#_Toc116212188)

[14.16 Aavocyte, Inc. 182](#_Toc116212189)

[14.16.1 AAVOT Technology 182](#_Toc116212190)

[14.16.2 Indications for AAVOT Therapy 183](#_Toc116212191)

[14.17 Beam Therapeutics, Inc. 184](#_Toc116212192)

[14.17.1 Base Editing Technology 184](#_Toc116212193)

[14.18 Bellicum Pharmaceuticals 185](#_Toc116212194)

[14.18.1 GoCAR Technology 185](#_Toc116212195)

[14.18.2 CaspaCIDe Safety Switch 185](#_Toc116212196)

[14.19 BioNTech 187](#_Toc116212197)

[14.19.1 BioNTech’s Engineered Cell Therapies 187](#_Toc116212198)

[14.9.2 BNT211 187](#_Toc116212199)

[14.19.3 BNT212 187](#_Toc116212200)

[14.20 Biosceptre 188](#_Toc116212201)

[14.20.1 nfP2X7 188](#_Toc116212202)

[14.20.2 Biosceptre’s Product Pipeline 188](#_Toc116212203)

[14.21 bluebird bio 189](#_Toc116212204)

[14.21.1 CAR-T Collaborations 189](#_Toc116212205)

[14.21.2 Collaboration with Celgene 189](#_Toc116212206)

[14.21.3 Collaboration with Bristol Myers Squibb 189](#_Toc116212207)

[14.21.4 Collaboration with TC BioPharm 190](#_Toc116212208)

[14.21.5 Collaboration with Inhibrx 190](#_Toc116212209)

[14.21.6 Collaboration with PsiOxus 190](#_Toc116212210)

[14.22 Bristol Myers Squibb/Celgene Corp. 191](#_Toc116212211)

[14.22.1 Products 191](#_Toc116212212)

[14.22.1.1 ABECMA (idecabtagene vicleucel) 191](#_Toc116212213)

[14.22.1.2 Breyanzi (lisocabtagene maraleucel) 191](#_Toc116212214)

[14.23 Cabaletta Bio 192](#_Toc116212215)

[14.23.1 CAAR Technology 192](#_Toc116212216)

[14.24 Carina Biotech 193](#_Toc116212217)

[14.25 CARsgen Therapeutics 194](#_Toc116212218)

[14.26 Cartesian Therapeutics 195](#_Toc116212219)

[TABLE 14.19: Cartesian’s Growing Product Pipeline 195](#_Toc116212220)

[14.27 CARTherics Pty Ltd. 196](#_Toc116212221)

[14.27.1 Technology 196](#_Toc116212222)

[14.28 Cellectis 197](#_Toc116212223)

[14.28.1 Product Candidates 197](#_Toc116212224)

[TABLE 14.20: Cellectis’ Products in Development 197](#_Toc116212225)

[14.29 CellPoint BV 198](#_Toc116212226)

[14.30 Celularity, Inc. 199](#_Toc116212227)

[14.30.1 P CAR-T 199](#_Toc116212228)

[14.31 Celyad Oncology 200](#_Toc116212229)

[14.31.1 Technologies 200](#_Toc116212230)

[14.31.2 All-In-One Vector Approach 201](#_Toc116212231)

[14.31.3 Pipeline 201](#_Toc116212232)

[14.32 Century Therapeutics, Inc. 202](#_Toc116212233)

[14.32.1 Century’s Approach 202](#_Toc116212234)

[14.32.2 Gene Editing Technology 203](#_Toc116212235)

[14.32.3 Proprietary Allo-Evasion Technology 204](#_Toc116212236)

[14.32.4 CAR and Protein Engineering 204](#_Toc116212237)

[14.32.5 Common Engineered iPSC Progenitors 205](#_Toc116212238)

[14.32.6 Streamlined Manufacturing 206](#_Toc116212239)

[14.32.7 Century’s Pipeline Overview 207](#_Toc116212240)

[14.33 Clade Therapeutics 208](#_Toc116212241)

[14.34 Coeptis Therapeutics, Inc. 208](#_Toc116212242)

[14.34.1 SNAP CAR-T 208](#_Toc116212243)

[14.35 Creative Biolabs 209](#_Toc116212244)

[14.35.1 CAR-T Therapy Development 209](#_Toc116212245)

[14.35.2 Biomarker Identification and Selection 209](#_Toc116212246)

[14.35.3 scFv Generation 210](#_Toc116212247)

[14.35.4 CAR-T Gene Packaging & Delivery 210](#_Toc116212248)

[14.35.5 Replication-Competent Virus Testing Service 210](#_Toc116212249)

[14.35.6 CAR Cell In Vitro Assay Service 211](#_Toc116212250)

[14.35.7 CAR-T Preclinical In Vivo Assay 211](#_Toc116212251)

[14.35.8 IND Development for CAR-T Cell Therapy 211](#_Toc116212252)

[14.35.9 GMP Production for CAR-T Products 211](#_Toc116212253)

[14.35.10 CAR-T Clinical Trials 212](#_Toc116212254)

[14.36 CRISPR Therapeutics 213](#_Toc116212255)

[14.36.1 CRISPR/Cas9 Immuno-Oncology Cell Therapy 213](#_Toc116212256)

[14.36.2 CRISPR/Cas9 Allogeneic CAR-T Design 213](#_Toc116212257)

[14.37 Curocell, Inc. 214](#_Toc116212258)

[17.37.1 OVIS Technology 214](#_Toc116212259)

[17.38 CytoSeek 215](#_Toc116212260)

[14.38.1 Technology 215](#_Toc116212261)

[14.38.2 Pipeline 215](#_Toc116212262)

[14.39 Cytovia Therapeutics 216](#_Toc116212263)

[14.39.1 Technology 216](#_Toc116212264)

[14.40 DiaCarta 217](#_Toc116212265)

[14.40.1 Personalized CAR-T Immunotherapy Platform 217](#_Toc116212266)

[14.41 Elicera Therapeutics AB 218](#_Toc116212267)

[14.41.1 iTANK CAR-T Technology 218](#_Toc116212268)

[14.41.2 Elicera’s Product Pipeline 218](#_Toc116212269)

[14.42 Eureka Therapeutics, Inc. 219](#_Toc116212270)

[14.42.1 Technology 219](#_Toc116212271)

[14.42.1.1 E-ALPHA Phage Display Platform 219](#_Toc116212272)

[14.42.1.2 ARTEMIS Cell Receptor Platform 219](#_Toc116212273)

[14.42.2 Eureka’s Product Pipeline 220](#_Toc116212274)

[14.43 EXUMA Biotech Corp. 221](#_Toc116212275)

[14.43.1 TMR CAR-T Technology 221](#_Toc116212276)

[14.44 Fate Therapeutics, Inc. 222](#_Toc116212277)

[14.45 Gilead Sciences, Inc. 223](#_Toc116212278)

[14.45.1 CAR-T Products 223](#_Toc116212279)

[14.45.1.1 TECARTUS (Brexucabtagene autoleucel) 223](#_Toc116212280)

[14.45.1.2 Yescarta (Axicabtagene ciloleucel) 223](#_Toc116212281)

[14.45.2 CAR-T Programs 224](#_Toc116212282)

[14.46 Gracell Biotechnologies 225](#_Toc116212283)

[14.46.1 FasTCAR 225](#_Toc116212284)

[14.46.2 TruUCAR 226](#_Toc116212285)

[14.46.3 SMART CART 226](#_Toc116212286)

[14.46.4 Gracell’s Clinical Pipeline 226](#_Toc116212287)

[14.47 IASO Biotherapeutics 227](#_Toc116212288)

[14.47.1 Technology Platforms 227](#_Toc116212289)

[14.47.1.1 Fully Human Antibody Discovery Platform (IMARS) 227](#_Toc116212290)

[14.47.1.2 High-Throughput Screening Platform for CAR-T Candidates 228](#_Toc116212291)

[14.47.1.3 Universal CAR-T Technology Platform 228](#_Toc116212292)

[14.47.1.4 Manufacturing Technology Platform 228](#_Toc116212293)

[14.47.2 IASO’s Diverse Product Pipeline 228](#_Toc116212294)

[14.48 iCell Gene Therapeutics 230](#_Toc116212295)

[14.48.1 CARvac Platform 230](#_Toc116212296)

[14.48.2 T-Cell Targeted CARs 230](#_Toc116212297)

[14.48.3 Non-Gene Edited Universal CARs 230](#_Toc116212298)

[14.48.4 C-TPS1 231](#_Toc116212299)

[14.48.5 Compound CARs 231](#_Toc116212300)

[14.48.5 Pipeline 231](#_Toc116212301)

[14.49 ImmPACT Bio 232](#_Toc116212302)

[14.49.1 Technologies 232](#_Toc116212303)

[14.49.1.1 Dual-Targeted CAR-T Cell Therapy 232](#_Toc116212304)

[14.49.1.2 ICAR Dual Targeting Technology 233](#_Toc116212305)

[14.49.1.3 TGF-B CARS Targeting TME 233](#_Toc116212306)

[14.50 Immuneel Therapeutics, Pvt. Ltd. 234](#_Toc116212307)

[14.51 Inceptor Bio 235](#_Toc116212308)

[14.51.1 Inceptor’s Technology Platforms 235](#_Toc116212309)

[14.52 Interius BioTherapeutics 236](#_Toc116212310)

[14.52.1 Core Technology 236](#_Toc116212311)

[14.53 Janssen Biotech, Inc. 237](#_Toc116212312)

[14.53.1 JNJ-4528 237](#_Toc116212313)

[14.54 JW Therapeutics 238](#_Toc116212314)

[14.54.1 Relma-cel (JWCAR029) 238](#_Toc116212315)

[14.55 Kite Pharma (Gilead) 239](#_Toc116212316)

[14.55.1 Kite’s Technology 239](#_Toc116212317)

[14.55.2 Kite’s Marketed Therapies 239](#_Toc116212318)

[14.55.2.1 Yescarta (Axicabtagene ciloleucel) 239](#_Toc116212319)

[14.55.2.2 Tecartus (Brexucabtagene autoleucel) 240](#_Toc116212320)

[14.55.3 Kite’s Pipeline Cancer Therapies 241](#_Toc116212321)

[14.56 Kuur Therapeutics 242](#_Toc116212322)

[14.56.1 Kuur’s Product Candidates 242](#_Toc116212323)

[14.57 Kyverna Therapeutics 243](#_Toc116212324)

[14.57.1 CAR-T Cells 243](#_Toc116212325)

[14.57.1.1 SynNotch CAR-T Cells 243](#_Toc116212326)

[14.57.1.2 SynReg T Cells 244](#_Toc116212327)

[14.58 Legend Biotech 246](#_Toc116212328)

[14.58.1 LCAR-B38M/JNJ-4528 246](#_Toc116212329)

[14.59 Leucid Bio 247](#_Toc116212330)

[14.59.1 Leucid’s Science 247](#_Toc116212331)

[14.59.2 Leucid’s Product Pipeline 247](#_Toc116212332)

[14.60 Luminary Therapeutics, Inc. 248](#_Toc116212333)

[14.60.1 BAFF CAR-T 248](#_Toc116212334)

[14.60.2 Universal Receptor 249](#_Toc116212335)

[14.60.3 Luminary Therapeutics’ Pipeline 249](#_Toc116212336)

[14.61 Lyell Immunopharma, Inc. 250](#_Toc116212337)

[14.61.1 Technologies 250](#_Toc116212338)

[14.61.1.1 Gen-R Technology 250](#_Toc116212339)

[14.61.1.2 Epi-R Technology 250](#_Toc116212340)

[14.62 MaxCyte, Inc. 251](#_Toc116212341)

[14.62.1 ExPERT Technology Platform 252](#_Toc116212342)

[14.62.1.1 ATx 252](#_Toc116212343)

[14.62.1.2 GTx 253](#_Toc116212344)

[14.62.1.3 STx 253](#_Toc116212345)

[14.62.1.4 VLx 254](#_Toc116212346)

[14.63 Minerva Biotechnologies Corporation 255](#_Toc116212347)

[14.63.1 Autologous huMNC2-CAR44 255](#_Toc116212348)

[14.64 Mnemo Therapeutics 256](#_Toc116212349)

[14.64.1 Mnemo’s Approach 256](#_Toc116212350)

[14.64.1.1 Mnemo’s 1XX CAR 256](#_Toc116212351)

[14.65 Mustang Bio 257](#_Toc116212352)

[14.66 Neukio Biotherapeutics 258](#_Toc116212353)

[14.66.1 iPSC-CAR-NK Technology 258](#_Toc116212354)

[14.67 NKarta, Inc. 259](#_Toc116212355)

[14.67.1 Technology 259](#_Toc116212356)

[14.67.2 NKarta’s Pipeline 260](#_Toc116212357)

[14.68 Noile-Immune Biotech 261](#_Toc116212358)

[14.68.1 PRIME Technology 261](#_Toc116212359)

[14.69 Novartis AG 262](#_Toc116212360)

[14.69.1 The Pioneers of CAR-T Cell & Gene Therapy 262](#_Toc116212361)

[14.69.2 Approval of Kymriah (tisagenlecleucel) 262](#_Toc116212362)

[14.70 Oncternal Therapeutics 263](#_Toc116212363)

[14.70.1 Oncternal’s Product Pipeline 263](#_Toc116212364)

[14.71 Orna Therapeutics 264](#_Toc116212365)

[14.71.1 oRNA Circular RNA 264](#_Toc116212366)

[14.71.2 oRNA’s Pipeline Products 264](#_Toc116212367)

[14.72 Oxford Biomedica plc 265](#_Toc116212368)

[14.72.1 LentiVector Platform 265](#_Toc116212369)

[14.72.2 LentiStable Platform 265](#_Toc116212370)

[14.72.3 Adeno-Associated Virus (AAV) Platform 266](#_Toc116212371)

[14.72.4 TRiP System 266](#_Toc116212372)

[14.73 PeproMene Bio, Inc. 267](#_Toc116212373)

[14.73.1 BAFFR CAR-T Cells 267](#_Toc116212374)

[14.73.2 Bispecific T Cell Engager (BiTE) 268](#_Toc116212375)

[14.73.3 CAR NK Cells 268](#_Toc116212376)

[14.74 Poseida Therapeutics, Inc. 270](#_Toc116212377)

[14.74.1 Platforms 270](#_Toc116212378)

[14.74.1.1 piggyBac 270](#_Toc116212379)

[14.74.1.2 Cas-CLOVER 271](#_Toc116212380)

[14.74.1.3 Gene Delivery 271](#_Toc116212381)

[14.74.1.4 TSCM Cells 271](#_Toc116212382)

[14.74.2 Pipeline Products 271](#_Toc116212383)

[14.74.2.1 P-BCMA-ALL01 272](#_Toc116212384)

[14.74.2.2 P-MUC1C-ALL01 272](#_Toc116212385)

[14.74.2.3 P-PSMA-ALL01 272](#_Toc116212386)

[14.74.2.4 Dual CAR Allogeneic Programs 272](#_Toc116212387)

[14.74.2.5 P-PSMA-101 273](#_Toc116212388)

[14.75 Precigen, Inc. 273](#_Toc116212389)

[14.75.1 Therapeutic Platforms 273](#_Toc116212390)

[14.75.1.1 UltraCAR-T 273](#_Toc116212391)

[14.75.1.2 AdenoVerse Immunotherapy 274](#_Toc116212392)

[14.75.1.3 ActoBiotics 275](#_Toc116212393)

[14.75.1.4 Multifunctional Therapeutics 275](#_Toc116212394)

[14.75.2 Technology Platforms 275](#_Toc116212395)

[14.75.2.1 UltraVector 275](#_Toc116212396)

[14.75.2.2 Sleeping Beauty System 276](#_Toc116212397)

[14.75.2.3 AdenoVerse 276](#_Toc116212398)

[14.75.2.4 UltraPorator 276](#_Toc116212399)

[14.75.2.5 RheoSwitch 276](#_Toc116212400)

[14.75.3 Precigen’s Pipeline 276](#_Toc116212401)

[14.76 Precision Biosciences 277](#_Toc116212402)

[14.76.1 ARCUS Genome Editing 277](#_Toc116212403)

[14.76.2 Precision’s CAR-T Immunotherapy Pipeline 278](#_Toc116212404)

[14.77 Prescient Therapeutics 279](#_Toc116212405)

[14.77.1 Technology 279](#_Toc116212406)

[14.77.1.1 OmniCAR 279](#_Toc116212407)

[14.77.1.2 CellPryme-M 279](#_Toc116212408)

[14.77.1.3 PTX-100 280](#_Toc116212409)

[14.77.1.4 PTX-200 280](#_Toc116212410)

[14.78 ProMab Biotechnologies, Inc. 281](#_Toc116212411)

[14.78.1 Products 281](#_Toc116212412)

[14.78.2 Services 281](#_Toc116212413)

[14.78.2.1 Cell Line Engineering Services 282](#_Toc116212414)

[14.78.2.2 Custom CAR-T Cell Development 282](#_Toc116212415)

[14.78.2.3 Custom CAR-NK Cell Development 283](#_Toc116212416)

[14.78.2.4 Custom CAR-Macrophage Cell Development 283](#_Toc116212417)

[14.78.2.5 Custom Gamma Delta T Cell Development 283](#_Toc116212418)

[14.78.3 Lentivirus Production 283](#_Toc116212419)

[14.78.4 mRNA-Lipid Nanoparticle Gene Delivery 284](#_Toc116212420)

[14.78.5 Cancer Stem Cell Line Services 284](#_Toc116212421)

[14.79 Quell Therapeutics, Ltd. 285](#_Toc116212422)

[14.79.1 Quell’s Platform 285](#_Toc116212423)

[14.80 Sorrento Therapeutics, Inc. 286](#_Toc116212424)

[14.80.1 DAR-T (Dimeric Antigen Receptor T Cell) 286](#_Toc116212425)

[14.81 SOTIO Biotech, A.S. 287](#_Toc116212426)

[14.81.1 SOTIO’s Pipeline 287](#_Toc116212427)

[14.82 Syngene International, Ltd. 288](#_Toc116212428)

[14.82.1 CAR-T Services 288](#_Toc116212429)

[14.83 Synthekine 290](#_Toc116212430)

[14.83.1 STK-009 + SYNCAR-001 290](#_Toc116212431)

[14.84 TC BioPharm 291](#_Toc116212432)

[14.84.1 Gamma Delta T Cells 291](#_Toc116212433)

[14.84.2 Cell Banks 292](#_Toc116212434)

[14.84.3 Co-Stim CAR-T 292](#_Toc116212435)

[14.84.4 TC BioPharm’s Product Pipeline 292](#_Toc116212436)

[14.84.5 Omnlmmune 293](#_Toc116212437)

[14.84.6 CAR-T Programs 293](#_Toc116212438)

[14.85 T-CURX 294](#_Toc116212439)

[14.85.1 CARAMBA Project 294](#_Toc116212440)

[14.85.2 imSAVAR Project 294](#_Toc116212441)

[14.86 Tessa Therapeutics, Ltd. 295](#_Toc116212442)

[14.87 Tmunity Therapeutics 296](#_Toc116212443)

[14.87.1 Technology 296](#_Toc116212444)

[14.87.2 Pipeline 296](#_Toc116212445)

[14.88 Umoja Biopharma 298](#_Toc116212446)

[14.88.1 Umoja’s Core Technology Platforms 298](#_Toc116212447)

[14.88.1.1 VivoVec in vivo Gene Delivery 298](#_Toc116212448)

[14.88.1.2 RACR/CAR in vivo Cell Programming 298](#_Toc116212449)

[14.88.1.3 TumorTag (Universal CAR Tumor Targeting) 299](#_Toc116212450)

[14.89 Vor Biopharma 300](#_Toc116212451)

[14.89.1 Vor Biopharma’s Ap[proach 300](#_Toc116212452)

[14.89.2 Vor’s Platform 300](#_Toc116212453)

[14.89.3 Vor’s Pipeline 300](#_Toc116212454)

[14.90 Wugen 302](#_Toc116212455)

[14.91 WuXi Advanced Therapies 303](#_Toc116212456)

[14.91.1 Closed-Process CAR-T Platform 303](#_Toc116212457)

[14.92 Xenetic Biosciences 305](#_Toc116212458)

[14.92.1 The DNase Platform Technology 305](#_Toc116212459)

[14.92.2 XCART Personalized CAR-T Platform Technology 305](#_Toc116212460)

[14.92.3 PolyXen PSA Technology Platform 306](#_Toc116212461)

[14.93 Xyphos Biosciences, Inc. 307](#_Toc116212462)

[14.93.1 ACCEL & UDC Technology 307](#_Toc116212463)

[14.93.2 convertibleCAR 307](#_Toc116212464)

[14.93.3 Univeral Donor Cells 308](#_Toc116212465)

**INDEX OF FIGURES**

[FIGURE 2.1: The Basic Structure of a T cell 24](#_Toc116212842)

[FIGURE 2.2: Binding of a T cell onto an Infected Cell 25](#_Toc116212843)

[FIGURE 2.3: Components of a CAR-T Cell 26](#_Toc116212844)

[FIGURE 2.4: The Three Domains of a CAR 27](#_Toc116212845)

[FIGURE 2.5: The First Generation CARs 27](#_Toc116212846)

[FIGURE 2.6: Second Generation CARs 28](#_Toc116212847)

[FIGURE 2.7: Third Generation CARs 28](#_Toc116212848)

[FIGURE 2.8: Fourth Generation CARs 29](#_Toc116212849)

[FIGURE 2.9: Fifth Generation CARs 30](#_Toc116212850)

[FIGURE 2.10: Antigens Present on Normal & Cancer Cells 30](#_Toc116212851)

[FIGURE 2.11: The Process of CAR-T Manufacturing 32](#_Toc116212852)

[FIGURE 2.12: Preparation & Administration of CAR-T Therapy 33](#_Toc116212853)

[FIGURE 3.1: The Five Generations of CARs 44](#_Toc116212854)

[FIGURE 3.2: A Package of Kymriah 50](#_Toc116212855)

[FIGURE 3.3: Yescarta in a Blood Bag 52](#_Toc116212856)

[FIGURE 3.4: Tecartus in a Blood Bag 54](#_Toc116212857)

[FIGURE 3.5: Abecma in a Blood Bag 57](#_Toc116212858)

[FIGURE 3.6: Relma-cel in a Blood Bag 58](#_Toc116212859)

[FIGURE 3.7: Carvykti in a Blood Bag 59](#_Toc116212860)

[FIGURE 4.1: The Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies 68](#_Toc116212861)

[FIGURE 4.2: G-Rex Bioreactors 69](#_Toc116212862)

[FIGURE 4.3: CliniMACS Prodigy 70](#_Toc116212863)

[FIGURE 4.4: Scaling Up of Allogeneic CAR-T Cells 71](#_Toc116212864)

[FIGURE 4.5: Operating Expenses in Autologous CAR-T Manufacturing 72](#_Toc116212865)

[FIGURE 4.6: Operating Expenses in Allogeneic CAR-T Manufacturing 73](#_Toc116212866)

[FIGURE 5.1: CAR-T Global Distribution in Clinical Trials 74](#_Toc116212867)

[FIGURE 6.1: CAR-T Patent Publications 79](#_Toc116212868)

[FIGURE 6.2: Granted CAR-T Patents 80](#_Toc116212869)

[FIGURE 6.3: Geographical Origin of CAR-T Patent Applications 81](#_Toc116212870)

[FIGURE 6.4: Top Ten CAR-T Patent Jurisdictions 82](#_Toc116212871)

[FIGURE 6.5: Affiliations of CAR-T Patent Applicants 83](#_Toc116212872)

[FIGURE 7.1: Percent Share of CAR-T Clinical Trials by Phase 91](#_Toc116212873)

[FIGURE 7.2: Percent Share of Hematological Malignancy Types in CAR-T Clinical Trials 92](#_Toc116212874)

[FIGURE 7.3: Simultaneous Targets by One CAR-T 92](#_Toc116212875)

[FIGURE 7.4: CAR-T Generations Used in Clinical Trials 93](#_Toc116212876)

[FIGURE 7.5: % Share of Ten Major Solid Tumor Indications in CAR-T Clinical Trials 94](#_Toc116212877)

[FIGURE 7.6: Hematological Malignancies v.s. Solid Cancers in CAR-T Clinical Trials 100](#_Toc116212878)

[FIGURE 7.7: Distribution of CAR-T Clinical Trials by ScFv Used 114](#_Toc116212879)

[FIGURE 7.8: Distribution of CAR-T Clinical Trials by Type of Vectors Used 115](#_Toc116212880)

[FIGURE 8.1: Number of Published CAR-T Papers in PubMed.gov 116](#_Toc116212881)

[FIGURE 8.2: Published PubMed Papers on the Five Generations of CAR-Ts 117](#_Toc116212882)

[FIGURE 8.3: Published PubMed Papers, Autologous v.s Allogeneic CAR-Ts 118](#_Toc116212883)

[FIGURE 8.4: Published CAR-T PubMed Papers on Solid & Liquid Cancers 119](#_Toc116212884)

[FIGURE 10.1: CAR-T Cell Treated Patients Registered in EBMT Registry 141](#_Toc116212885)

[FIGURE 11.1: Global Incidence of Blood Cancers & Death in 2020 142](#_Toc116212886)

[FIGURE 11.2: Percent Distribution of New Leukemia Cases in the U.S. by Type 145](#_Toc116212887)

[FIGURE 12.1: Estimated Global Market for CAR-T Therapy by Product, 2022-2030 157](#_Toc116212888)

[FIGURE 12.2: Global Market for CAR-T by Geography, 2021-2030 159](#_Toc116212889)

[FIGURE 12.3: Global Market for CAR-T Therapies by Indication, 2021-2030 160](#_Toc116212890)

[FIGURE 14.1: Proprietary Cell Platform Process 165](#_Toc116212891)

[FIGURE 14.2: Atara’s Differentiated Approach to Allogeneic Cell Therapy 176](#_Toc116212892)

[FIGURE 14.3: Schematic of P CAR-T with TCR-KO 199](#_Toc116212893)

[FIGURE 14.4: All-In-One Vector Approach 201](#_Toc116212894)

[FIGURE 14.5: Century’s Approach in Developing Drug Product 202](#_Toc116212895)

[FIGURE 14.6: Century’s Precision Gene Editing Technology 203](#_Toc116212896)

[FIGURE 14.7: Century’s Allo-Evasion Technology 204](#_Toc116212897)

[FIGURE 14.8: Century’s CAR Engineering 205](#_Toc116212898)

[FIGURE 14.9: Century’s Common Engineered iPSC Progenitors 206](#_Toc116212899)

[FIGURE 14.10: Difference between Donor-Derived and iPSC-Derived Cell Expansion 207](#_Toc116212900)

[FIGURE 14.11: OVIS Technology 214](#_Toc116212901)

[FIGURE 14.12: FasTCAR vs. Conventional CAR-T Manufacturing Process 225](#_Toc116212902)

[FIGURE 14.13: Schematic of CD19/CD20 CAR-T Technology 232](#_Toc116212903)

[FIGURE 14.14: Schematic of SynNotch CAR-T Cells Recognizing Target Cells 244](#_Toc116212904)

[FIGURE 14.15: Schematic of Reprogrammed SynReg T Cells Targeting Disease Tissues 245](#_Toc116212905)

[FIGURE 14.16: Schematic of BAFF CAR-T’s Action 248](#_Toc116212906)

[FIGURE 14.17: ATx 252](#_Toc116212907)

[FIGURE 14.18: GTx 253](#_Toc116212908)

[FIGURE 14.19: STx 254](#_Toc116212909)

[FIGURE 14.20: MaxCyte VLx 254](#_Toc116212910)

[FIGURE 14.21: NKarta’s Engineered CAR-NK Cell 259](#_Toc116212911)

[FIGURE 14.22: Mechanism of Action of BAFFR CAR-T Cells 267](#_Toc116212912)

[FIGURE 14.23: Mechanism of Action of BAFF-R BiTE 268](#_Toc116212913)

[FIGURE 14.24: PeproMene’s CAR NK Cells 269](#_Toc116212914)

[FIGURE 14.25: UltraCAR-T Cell 274](#_Toc116212915)

[FIGURE 14.26: WuXi’s Closed-Process CAR-T Platform 304](#_Toc116212916)

[FIGURE 14.27: Convertible CAR Parts 308](#_Toc116212917)

[FIGURE 14.28: Universal Donor Cells 308](#_Toc116212918)

**INDEX OF TABLES**

[TABLE 2.1: Potential CAR-T Targeted Antigens Present on Hematological Malignancies 31](#_Toc116213187)

[TABLE 2.2: Key Differences between the available Vectors 32](#_Toc116213188)

[TABLE 2.3: The Seven CAR-T Therapies Available in the Market: A Brief Overview 34](#_Toc116213189)

[TABLE 2.3: (CONTINUED) 35](#_Toc116213190)

[TABLE 2.3: (CONTINUED) 36](#_Toc116213191)

[TABLE 2.4: Toxicities Associated with CAR-T Treatment 37](#_Toc116213192)

[TABLE 2.5: Strategies for the Future of CAR-T Therapies 38](#_Toc116213193)

[TABLE 2.6: A Short List of ongoing CAR-T Studies on Solid Tumors 40](#_Toc116213194)

[TABLE 2.7: New Target Antigens and New Target Cancers 41](#_Toc116213195)

[TABLE 2.8: A Non-Comprehensive List of Allogeneic CAR-T Companies 42](#_Toc116213196)

[TABLE 3.1: History of Development of CAR-T Cell Therapy 45](#_Toc116213197)

[TABLE 3.2: Approved CAR-T Products, their Developers and Indications 49](#_Toc116213198)

[TABLE 3.3: Other Promising CAR-T Product Candidates 61](#_Toc116213199)

[TABLE 3.4: Increased CAR-T Activity 64](#_Toc116213200)

[TABLE 3.5: Very Small Patient Population Addressed by CAR-T Therapy 65](#_Toc116213201)

[TABLE 5.1: CAR-T Target Antigens on Hematalogical Malignancies 75](#_Toc116213202)

[TABLE 5.2: CAR-T Target Antigens on Solid Tumors 76](#_Toc116213203)

[TABLE 6.1: Top 20 Companies in CAR-T Patent Landscape 84](#_Toc116213204)

[TABLE 6.2: Top 20 Research Centers in CAR-T Patent Landscape 85](#_Toc116213205)

[TABLE 6.3: Top Twenty CAR-T Inventors 86](#_Toc116213206)

[TABLE 6.4: Top Five CAR-T Patents with Most Family Members 87](#_Toc116213207)

[TABLE 6.5: Top Five CAR-T Patents with Most Inventors in Co-Authorship 87](#_Toc116213208)

[TABLE 6.6: Top Five Patents with Most Co-Applicants 88](#_Toc116213209)

[TABLE 6.7: Top 5 CAR-T Patents with Most Co-Applicants 88](#_Toc116213210)

[TABLE 7.1: Number of CAR-T Clinical Trials by Country 90](#_Toc116213211)

[TABLE 7.2: Percent Target Distribution of CAR-T Clinical Trials 95](#_Toc116213212)

[TABLE 7.3: CAR-T Targeted Biomarkers in the U.S. Clinical Trials 96](#_Toc116213213)

[TABLE 7.4: CAR-T Targeted Biomarkers in Chinese Clinical Trials 97](#_Toc116213214)

[TABLE 7.5: CAR-T Targeted Indications in the U.S. Clinical Trials 98](#_Toc116213215)

[TABLE 7.6: CAR-T Targeted Indications in the U.S. Clinical Trials 99](#_Toc116213216)

[TABLE 7.7: CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S. 101](#_Toc116213217)

[TABLE 7.7: (CONTINUED) 102](#_Toc116213218)

[TABLE 7.8: CAR-T ClinicAl Trial Sponsor Companies & Institutions in China 103](#_Toc116213219)

[TABLE 7.8: (CONTINUED) 104](#_Toc116213220)

[TABLE 7.8: (CONTINUED) 105](#_Toc116213221)

[TABLE 7.9: CAR-T Clinical Trial Sponsor Companies & Institutions in other Countries 106](#_Toc116213222)

[TABLE 7.10: Clinical Trials of Fourth, Fifth and Gene Edited CAR-Ts 109](#_Toc116213223)

[TABLE 7.10: (CONTINUED) 110](#_Toc116213224)

[TABLE 7.10: (CONTINUED) 111](#_Toc116213225)

[TABLE 7.10: (CONTINUED) 112](#_Toc116213226)

[TABLE 7.10: (CONTINUED) 113](#_Toc116213227)

[TABLE 8.1: A Short List of NIH Funding for CAR-T Research in 2022 120](#_Toc116213228)

[TABLE 8.1: (CONTINUED) 121](#_Toc116213229)

[TABLE 10.1: Hospital Reimbursement, Proposed & Final Rule FY 2022 and FY 2023 135](#_Toc116213230)

[TABLE 10.2: List Prices of Kymriah and Yescarta in Europe 136](#_Toc116213231)

[TABLE 10.3: Cost Components of Pre- and Post-CAR-T Cell Therapy, in E.U. 136](#_Toc116213232)

[TABLE 10.4: Average Total Costs Pre- and Post CAR-T Cell Administration in E.U. 137](#_Toc116213233)

[TABLE 10.5: Reimbursement for CAR-T Thrapies in France 138](#_Toc116213234)

[TABLE 10.6: Reimbursement for CAR-T Therapies in Germany 138](#_Toc116213235)

[TABLE 10.7: Reimbursement for CAR-T Therapies in Italy 139](#_Toc116213236)

[TABLE 10.8: Reimbursement for CAR-T Therapies in Spain 139](#_Toc116213237)

[TABLE 10.9: Reimbursement for CAR-T Therapies in U.K. 140](#_Toc116213238)

[TABLE 11.1: Cost of Treating Blood Cancers 153](#_Toc116213239)

[TABLE 12.1: Estimated Global Market for CAR-T Therapy by Product, 2021-2030 157](#_Toc116213240)

[TABLE 12.2: Global Market for CAR-T by Geography, 2021-2030 159](#_Toc116213241)

[TABLE 12.3: Global Market for CAR-T Therapies by Indication, 2021-2030 160](#_Toc116213242)

[TABLE 14.1: Adicet’s Broad Pipeline in Cancer 165](#_Toc116213243)

[TABLE 14.2: AffyImmune’s Affinity-Tuned Pipeline Products 166](#_Toc116213244)

[TABLE 14.3: Alaunos’ Advanced Platform Targeting Solid Tumors 167](#_Toc116213245)

[TABLE 14.4: Aleta’s CAR-T Engager Pipeline in High Unmet Need Indications 168](#_Toc116213246)

[TABLE 14.5: Allogene’s AlloCAR-T Pipeline 169](#_Toc116213247)

[TABLE 14.6: Anixa’s Product Pipeline 170](#_Toc116213248)

[TABLE 14.7: Arbele’s Product Pipeline 172](#_Toc116213249)

[TABLE 14.8: Arcellx’s Current Product Pipeline 174](#_Toc116213250)

[TABLE 14.9: Artiva’s NK Cell Therapy Pipeline for Cancer 175](#_Toc116213251)

[TABLE 14.10: Atara’s Robust Product Pipeline 177](#_Toc116213252)

[TABLE 14.11: Autolus’ Therapies in Development 179](#_Toc116213253)

[TABLE 14.12: AvenCell’s Clinical and Preclinical Pipeline 181](#_Toc116213254)

[TABLE 14.13: Beam’s Product Pipeline 184](#_Toc116213255)

[TABLE 14.14: Bellicum’s Pipeline of Investigational Immunotherapies 186](#_Toc116213256)

[TABLE 14.15: Biosceptre’s Product Pipeline 188](#_Toc116213257)

[TABLE 14.16: Cabaletta’s Autoimmune Therapy Candidates in Development 193](#_Toc116213258)

[TABLE 14.17: Carina Biotech’s Clinical Programs 193](#_Toc116213259)

[TABLE 14.18: CARsgen’s Product Pipeline 194](#_Toc116213260)

[TABLE 14.21: Celyad’s Diversified Pipeline 201](#_Toc116213261)

[TABLE 14.22: Century’s Pipeline Overview 207](#_Toc116213262)

[TABLE 14.23: CRISPR Therapeutics’ Immuno-Oncology Programs 213](#_Toc116213263)

[TABLE 14.24: CytoSeek’s Pipeline Product Candidates 215](#_Toc116213264)

[TABLE 14.25: Cytovia’s Product Pipeline 216](#_Toc116213265)

[TABLE 14.26: Elicera’s Product Portfolio 218](#_Toc116213266)

[TABLE 14.27: Eureka’s Product Pipeline 220](#_Toc116213267)

[TABLE 14.28: EXUMA’s Pipeline Assets 221](#_Toc116213268)

[TABLE 14.29: Fate’s Product Pipeline 222](#_Toc116213269)

[TABLE 14.30: Gilead’s Ongoing CAR-T Programs 224](#_Toc116213270)

[TABLE 14.31: Gracell’s Clinical Pipeline 226](#_Toc116213271)

[TABLE 14.32: IASO’s Diverse Product Pipeline 229](#_Toc116213272)

[TABLE 14.33: iCell Gene’s Product Pipeline 231](#_Toc116213273)

[TABLE 14.34: ImmPACT Bio’s Product Pipeline 233](#_Toc116213274)

[TABLE 14.35: Inceptor’s Diversified Cell Therapy Programs 235](#_Toc116213275)

[TABLE 14.36: JW Therapeutics’ Product Pipeline 238](#_Toc116213276)

[TABLE 14.37: Kite’s Pipeline Cancer Therapies 241](#_Toc116213277)

[TABLE 14.38: Legend’s Autologous Product Pipeline for Hematological Cancers 246](#_Toc116213278)

[TABLE 14.39: Legend’s Allogeneic Product Pipeline for Hematological & Solid Cancers 246](#_Toc116213279)

[TABLE 14.40: Leucid’s Product Pipeline 247](#_Toc116213280)

[TABLE 14.41: Luminary’s Product Pipeline 249](#_Toc116213281)

[TABLE 14.42: Lyell’s Diverse Pipeline Targeting Solid Tumor Cancers 251](#_Toc116213282)

[TABLE 14.43: Minerva’s Pipeline Products for Solid Tumors 255](#_Toc116213283)

[TABLE 14.44: Mustang Bio’s Five In Licensed CAR-T Programs 257](#_Toc116213284)

[TABLE 14.45: NKarta’s Product Pipeline 260](#_Toc116213285)

[TABLE 14.46: Noile-Immune’s PRIME-based Pipeline Products 261](#_Toc116213286)

[TABLE 14.47: Oncternal’s Product Pipeline 263](#_Toc116213287)

[TABLE 14.48: oRNA’s Pipeline Products 264](#_Toc116213288)

[TABLE 14.49: Oxford Biomedica’s CDMO Services Pipeline 266](#_Toc116213289)

[TABLE 14.50: PeproMene’s Product Pipeline 269](#_Toc116213290)

[TABLE 14.51: Poseida’s Allogeneic & Autologous Product Candidates 271](#_Toc116213291)

[TABLE 14.52: Precigen’s Pipeline 277](#_Toc116213292)

[TABLE 14.53: Precision’s CAR-T Immunotherapy Pipeline 278](#_Toc116213293)

[TABLE 14.54: Quell’s Pipeline 285](#_Toc116213294)

[TABLE 14.55: SOTIO’s Pipeline 287](#_Toc116213295)

[TABLE 14.56: Tessa’s Product Pipeline 295](#_Toc116213296)

[TABLE 14.57: Tmunity’s Product Pipeline 297](#_Toc116213297)

[TABLE 14.58: Umoja’s Product Pipeline 299](#_Toc116213298)

[TABLE 14.59: Vor Biopharma’s Product Pipeline against Blood Cancers 301](#_Toc116213299)

[TABLE 14.60: Wugen’s Product Pipeline 302](#_Toc116213300)

[TABLE 14.61: Xenetic’s Product Pipeline 306](#_Toc116213301)

[TABLE 14.62: Xyphos’ Product Pipeline 309](#_Toc116213302)

About BioInformant:

BioInformant is the first and only market research firm to specialize in the Regenerative Medicine (RM) Industry.

BioInformant research has been cited by prominent news outlets that include Nature Biotechnology, the Wall Street Journal, CBS News, Yahoo Finance, Medical Ethics, AABB, Xconomy, and Vogue Magazine.

BioInformant serves Fortune 500 companies that include Pfizer, Goldman Sachs, and Beckton Dickinson, as well as industry start-ups and market leaders worldwide.

For more about our company and clients, visit [www.BioInformant.com](http://www.BioInformant.com).

BioInformant Worldwide, LLC

www.BioInformant.com